Arcus Biosciences, Inc. (RCUS): Shareholders' Equity
$631.00M
As of 2025-12-31
$464.00M
As of 2026-06-30
-1.3%
3-year compound annual growth
+4.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $631.00M | +30.1% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $485.00M | +5.0% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $462.00M | -29.7% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $657.00M | -22.0% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $842.00M | +67.7% | 2024-02-21, Balance as of period end |
| 2020-12-31 | $502.00M | +206.4% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $163.84M | -30.3% | 2022-02-23, Balance as of period end |
| 2018-12-31 | $234.94M | n/m | 2021-02-25, Balance as of period end |
| 2017-12-31 | -$72.33M | n/m | 2019-03-05, Balance as of period end |
| 2016-12-31 | -$19.99M | n/a | 2019-03-05, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $631.00M | +30.1% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $364.05M | -13.6% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $32.61M | n/m |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $37.21M | -47.5% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $433.90M | -22.8% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $130.34M | +41.5% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.02B | +22.5% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $307.42M | +453.3% |
Compare RCUS, KROS, SDGR, AKBA side by side · Screen every company in Pharmaceutical Preparations ↗